Table 5. Demographic, Clinical, and Paraclinical Characteristics of Patients Achieved or Failed to Achieve ETR or SVR During the Study Period .
| Parameter | Achieved ETR or SVR (n = 75) | Not achieved ETR or SVR (n = 74) | OR (95% CI) | P value |
|---|---|---|---|---|
| Sex | 1.207 (0.35 - 4.16) | 0.766 | ||
| Male, No (%) | 68 (90.7) | 66 (89.2) | ||
| Female, No (%) | 7 (9.3) | 8 (10.8) | ||
| Age, y | 0.524 (0.235 - 1.166) | 0.113 | ||
| < 40, No (%) | 49 (65.3) | 35 (47.3) | ||
| ≥ 40, No (%) | 26 (34.7) | 39 (52.7) | ||
| Weight, kg | 0.654 (0.294 - 1.453) | 0.297 | ||
| ≤ 75, No (%) | 47 (62.7) | 40 (54.1) | ||
| > 75, No (%) | 28 (37.3) | 34 (45.9) | ||
| HCV genotype | 1.888 (0.711 - 5.017) | 0.202 | ||
| 1, No (%) | 21 (28) | 44 (59.5) | ||
| Non-1, No (%) | 53 (70.7) | 28 (37.8) | ||
| Unknown, No (%) | 1 (1.3) | 2 (2.7) | ||
| Pre-treatment viral load, IU/ml | 1.004 (0.539 - 1.869) | 0.99 | ||
| ≤ 800,000, No (%) | 43 (57.3) | 34 (45.9) | ||
| > 800,000, No (%) | 27 (36) | 34 (45.9) | ||
| Unknown, No (%) | 5 (6.7) | 6 (8.1) | ||
| Pre-treatment serum alanine aminotransferase level, IU/l | 0.932 (0.497 - 1.746) | 0.825 | ||
| < 3 times higher than the upper limit of normal, No (%) | 47 (62.7) | 51 (68.9) | ||
| ≥ 3 times higher than the upper limit of normal, No (%) | 25 (33.3) | 17 (22.9) | ||
| Unknown, No (%) | 3 (4) | 6 (8.1) | ||
| Pretreatment liver fibrosis stage | 1.149 (0.62 - 2.129) | 0.66 | ||
| ≤ 2, No (%) | 11 (14.7) | 19 (25.7) | ||
| > 2, No (%) | 6 (8) | 16 (21.6) | ||
| Unknown, No (%) | 58 (77.3) | 39 (52.7) | ||
| (Peg) Interferon alpha adherence | 1.868 (0.556 - 6.275) | 0.312 | ||
| < 80, No (%) | 32 (42.7) | 53 (71.6) | ||
| ≥ 80, No (%) | 43 (57.3) | 21 (28.4) | ||
| Ribavirin adherence | 3.295 (1.184 - 9.168) | 0.022 | ||
| < 80, No (%) | 25 (33.3) | 49 (66.2) | ||
| ≥ 80, No (%) | 50 (66.7) | 25 (33.8) | ||
| Combined anti-HCV adherence | 0.91 (0.184 - 4.508) | 0.908 | ||
| < 80, No (%) | 54 (72) | 61 (82.4) | ||
| ≥ 80, No (%) | 21 (28) | 13 (17.6) |